The acute schistosomiasis mansoni ameliorates metabolic syndrome in the C57BL/6 mouse model

Filomeno, Carlos Eduardo da Silva; Costa-Silva, Michele; Corrêa, Christiane Leal; Neves, Renata Heisler; Mandarim-de-Lacerda, Carlos Alberto; Machado-Silva, José Roberto

doi:10.1016/j.exppara.2020.107889

Cited by 9 publications

(10 citation statements)

References 45 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Forty-three of these studies reported on total cholesterol [6][7][8][13][14][15][16][17]. Of these, 28 reported on participants infected with Schistosoma species or with mixed helminths that included Schistosoma species [6,7,13,15,[25][26][27][28]30,31,35,37,[39][40][41][42][43][44]46,[48][49][50][51][52][53][54][55]. These 28 studies mostly reported that infected individuals or those challenged with helminth products had lower total cholesterol than uninfected participants.…”

Section: Plos Neglected Tropical Diseasesmentioning

confidence: 99%

“…These 28 studies mostly reported that infected individuals or those challenged with helminth products had lower total cholesterol than uninfected participants. Including all helminths in other studies, 96% (24 of 25 total studies, which consisted of 11 human and 13 animal studies with 1 mixed study) that reported a relationship between helminth infection and lower total cholesterol found this inverse association to be significant [13,17,[24][25][26][27][28][29][30][31]33,35,[38][39][40][41]44,[46][47][48][49][50][51]54,55]. In contrast, 6 studies (14%, all with different helminths with 4 human and 2 animal studies) reported associations with increased total cholesterol [6,20,21,33,34,36], and 13 (30%, 10 human and 3 animal studies, of which 6 examined schistosome infections) demonstrated no effect of infection on total cholesterol [7,8,[14][15][16]22,23,32,36,37,42,43,53].…”

Section: Plos Neglected Tropical Diseasesmentioning

confidence: 99%

“…Twenty-nine studies reported on LDL [6][7][8][13][14][15][16][17]22,25,[27][28][29][30][34][35][36]39,42,43,[45][46][47][48][50][51][52][53][54], and the majority of these [19] focused on those infected with Schistosoma species. Eighteen (10 human, 8 animal) of the 29 studies (62%) found infected participants to have lower LDL than uninfected participants [7,13,16,17,25,[27][28][29][30]34,35,39,[45][46][47][48]50,51,53], of which 11 were in those with schistosome infections. By comparison, 3 studies (10%; 2 human, 1 animal) reported highe...…”

Section: Plos Neglected Tropical Diseasesmentioning

confidence: 99%

See 2 more Smart Citations

Effects of helminths and anthelmintic treatment on cardiometabolic diseases and risk factors: A systematic review

et al. 2023

View full text Add to dashboard Cite

Background Globally, helminth infections and cardiometabolic diseases often overlap in populations and individuals. Neither the causal relationship between helminth infections and cardiometabolic diseases nor the effect of helminth eradication on cardiometabolic risk have been reviewed systematically in a large number of human and animal studies. Methods We conducted a systematic review assessing the reported effects of helminth infections and anthelmintic treatment on the development and/or severity of cardiometabolic diseases and risk factors. The search was limited to the most prevalent human helminths worldwide. This study followed PRISMA guidelines and was registered prospectively in PROSPERO (CRD42021228610). Searches were performed on December 10, 2020 and rerun on March 2, 2022 using Ovid MEDLINE ALL (1946 to March 2, 2022), Web of Science, Cochrane Library, Global Index Medicus, and Ovid Embase (1974 to March 2, 2022). Randomized clinical trials, cohort, cross-sectional, case-control, and animal studies were included. Two reviewers performed screening independently. Results Eighty-four animal and human studies were included in the final analysis. Most studies reported on lipids (45), metabolic syndrome (38), and diabetes (30), with fewer on blood pressure (18), atherosclerotic cardiovascular disease (11), high-sensitivity C-reactive protein (hsCRP, 5), and non-atherosclerotic cardiovascular disease (4). Fifteen different helminth infections were represented. On average, helminth-infected participants had less dyslipidemia, metabolic syndrome, diabetes, and atherosclerotic cardiovascular disease. Eleven studies examined anthelmintic treatment, of which 9 (82%) reported post-treatment increases in dyslipidemia, metabolic syndrome, and diabetes or glucose levels. Results from animal and human studies were generally consistent. No consistent effects of helminth infections on blood pressure, hsCRP, or cardiac function were reported except some trends towards association of schistosome infection with lower blood pressure. The vast majority of evidence linking helminth infections to lower cardiometabolic diseases was reported in those with schistosome infections. Conclusions Helminth infections may offer protection against dyslipidemia, metabolic syndrome, diabetes, and atherosclerotic cardiovascular disease. This protection may lessen after anthelmintic treatment. Our findings highlight the need for mechanistic trials to determine the pathways linking helminth infections with cardiometabolic diseases. Such studies could have implications for helminth eradication campaigns and could generate new strategies to address the global challenge of cardiometabolic diseases.

show abstract

Section: Plos Neglected Tropical Diseasesmentioning

confidence: 99%

Section: Plos Neglected Tropical Diseasesmentioning

confidence: 99%

Section: Plos Neglected Tropical Diseasesmentioning

confidence: 99%

See 1 more Smart Citation

Effects of helminths and anthelmintic treatment on cardiometabolic diseases and risk factors: A systematic review

et al. 2023

View full text Add to dashboard Cite

show abstract

“…da Silva Filomeno CE et al. demonstrated that Schistosoma mansoni ( S. mansoni ) infection improves glucose tolerance, body mass and liver steatosis in HFD mice but aggravates pathological damage to the liver in mice ( 98 ). Similarly, Taenia pisiformis infection decreases body weight and cholesterol level in obese rabbits and changes the metabolic features in rabbits ( 99 ).…”

Section: Pathogenesis Of Nafldmentioning

confidence: 99%

Helminth infection and helminth-derived products: A novel therapeutic option for non-alcoholic fatty liver disease

Liu

Jiang

et al. 2022

Front. Immunol.

View full text Add to dashboard Cite

Non-alcoholic fatty liver disease (NAFLD) is closely related to obesity, diabetes, and metabolic syndrome (MetS), and it has become the most common chronic liver disease. Helminths have co-evolved with humans, inducing multiple immunomodulatory mechanisms to modulate the host’s immune system. By using their immunomodulatory ability, helminths and their products exhibit protection against various autoimmune and inflammatory diseases, including obesity, diabetes, and MetS, which are closely associated with NAFLD. Here, we review the pathogenesis of NAFLD from abnormal glycolipid metabolism, inflammation, and gut dysbiosis. Correspondingly, helminths and their products can treat or relieve these NAFLD-related diseases, including obesity, diabetes, and MetS, by promoting glycolipid metabolism homeostasis, regulating inflammation, and restoring the balance of gut microbiota. Considering that a large number of clinical trials have been carried out on helminths and their products for the treatment of inflammatory diseases with promising results, the treatment of NAFLD and obesity-related diseases by helminths is also a novel direction and strategy.

show abstract

“…Recently, these findings have been confirmed in HFD-fed, S. mansoni -infected mice that showed an improvement of their metabolic syndrome features. However, these beneficial effects developed at the expense of more advanced liver injury, suggesting the presence of both favorable as detrimental effects of schistosomal infection (da Silva Filomeno et al 2020 ).…”

Section: Bacteria and Parasitesmentioning

confidence: 99%

Infections at the nexus of metabolic-associated fatty liver disease

et al. 2021

View full text Add to dashboard Cite

Metabolic-associated fatty liver disease (MAFLD) is a chronic liver disease that affects about a quarter of the world population. MAFLD encompasses different disease stadia ranging from isolated liver steatosis to non-alcoholic steatohepatitis (NASH), fibrosis, cirrhosis and hepatocellular carcinoma. Although MAFLD is considered as the hepatic manifestation of the metabolic syndrome, multiple concomitant disease-potentiating factors can accelerate disease progression. Among these risk factors are diet, lifestyle, genetic traits, intake of steatogenic drugs, male gender and particular infections. Although infections often outweigh the development of fatty liver disease, pre-existing MAFLD could be triggered to progress towards more severe disease stadia. These combined disease cases might be underreported because of the high prevalence of both MAFLD and infectious diseases that can promote or exacerbate fatty liver disease development. In this review, we portray the molecular and cellular mechanisms by which the most relevant viral, bacterial and parasitic infections influence the progression of fatty liver disease and steatohepatitis. We focus in particular on how infectious diseases, including coronavirus disease-19, hepatitis C, acquired immunodeficiency syndrome, peptic ulcer and periodontitis, exacerbate MAFLD. We specifically underscore the synergistic effects of these infections with other MAFLD-promoting factors. Keywords Metabolic-associated fatty liver disease (MAFLD) • Non-alcoholic steatohepatitis (NASH) • Infectious diseases • Lipid metabolism • Liver • SARS-CoV-2 • Human immunodeficiency virus • Hepatitis C • Helicobacter pylori • Klebsiella pneumoniae

show abstract

The acute schistosomiasis mansoni ameliorates metabolic syndrome in the C57BL/6 mouse model

Cited by 9 publications

References 45 publications

Effects of helminths and anthelmintic treatment on cardiometabolic diseases and risk factors: A systematic review

Effects of helminths and anthelmintic treatment on cardiometabolic diseases and risk factors: A systematic review

Helminth infection and helminth-derived products: A novel therapeutic option for non-alcoholic fatty liver disease

Infections at the nexus of metabolic-associated fatty liver disease

Contact Info

Product

Resources

About